Medical Research Council

The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15).

Newcastle University scientists led by Dr. Shoba Amarnath have discovered why over 60% of cancer patients fail to respond to immune checkpoint blockade therapy, identifying regulatory T cells as key drivers of resistance.

Researchers developed an AI test that can predict which men with high-risk prostate cancer will benefit most from abiraterone treatment by analyzing tumor images.

A £1.7 million clinical trial called "Stratify Lupus" will test if a blood biomarker (IgA2 anti-dsDNA) can identify lupus patients who would respond to a novel combination of rituximab and belimumab.

The Dementia Trials Accelerator will receive £20m in government funding to significantly increase UK participation in dementia clinical trials.

A phase 3 study presented at ESMO 2024 indicates transdermal estradiol (tE2) is as effective as LHRH agonists for androgen suppression in high-risk, non-metastatic prostate cancer.

Pharmaceutical companies are increasingly turning to behavioral science principles to overcome barriers in prescribing patterns and drive adoption of new therapies, moving beyond traditional educational approaches.

Major UK medical research funders allocate less than 1% of their budgets to rare disease research, despite these conditions consuming 10% of the NHS specialized services budget.

The European Medicines Agency has committed to proactive publication of clinical trial data starting January 2014, enabling independent analysis of evidence used for drug approvals.